Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Letters to the Editor: Feedback from the Readers

Staff  |  Issue: March 2010  |  March 1, 2010

No Such Thing as Fibromyalgia

The October issue of The Rheumatologist featured an article on fibromyalgia by Daniel Clauw. Fibromyalgia does not exist. What is called fibromyalgia is part of the spectrum of chronic pain. The tender points are tender in everyone. Fibrous tissue and muscle are not involved. In other words, fibromyalgia is a misnomer. Like silicone breast implant syndrome and other now-forgotten diseases, it will disappear.

George E. Ehrlich, MD
Master, ACR

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

 

Dr. Clauw Responds:

To Dr. Ehrlich, thank you for your comments. I am quite aware that some people refuse to change their minds even in the face of overwhelming data.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Daniel J. Clauw, MD
Professor of Anesthesiology and Medicine (Rheumatology)
University of Michigan in Ann Arbor

 

Fibromyalgia Controversy

I read Dr. Clauw’s recent review of the pathogenesis and therapy of fibromyalgia (FM) with a good deal of interest.1,2 While his description of FM as an example of “central [nervous system] sensitization (CS)” resulting in pain amplification has appeal on a heuristic basis, I believe that it fails to identify a fundamental pathophysiologic explanation for the initiation and perpetuation of pain in the FM syndrome.

Dr. Clauw’s construct suggests the presence of certain “environmental stressors” that “trigger” FM in the susceptible individual, but then disappear (at least from that individual’s immediate environment), while leaving a mysteriously self-perpetuating CS/FM in its wake. This “non-nociceptive” form of CS (see Table 2 in Reference 1) is deemed to be self-evident since there are, Dr. Clauw says, no—or very few—peripheral indicators of tissue damage in FM. Supporting evidence for these assertions includes abnormal brain functional imaging studies (showing areas of hyperactive pain integration), and a clinical, pain-lessening effect for centrally acting pharmacological therapies, such as amitrptyline and pregabalin.

Dr. Clauw’s review is worthy of comment for a number of reasons. First, he has nicely sensitized rheumatologists, who are better known for their appreciation of the immune system and for being students of inflammation than for being neurophysiologists, to the role of CS in rheumatic disease pain production. I am afraid, however, that he has left the impression that FM is a disorder primarily of the central nervous system. He does not, for example, point out that many, and probably most, CS syndromes require constant peripheral nociceptive input in order to be maintained,3,4 though this maintenance may require only low levels of continuing nociceptive stimulation.5 The larger question for the rheumatologist may, therefore, revolve around determining from where and how that nociceptive input continues to arise in FM.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Education & Training Tagged with:Fibromialgia

Related Articles

    Revising Fibromyalgia: One Year Later

    July 12, 2011

    The 2010 ACR fibromyalgia criteria capture the broader clinical picture and help ensure more appropriate diagnosis and management by primary care

    Neurological Piece of the Fibromyalgia Puzzle

    November 1, 2009

    Exploring the peripheral and central elements of pain in FM

    Similarities to Fibromyalgia Found in Post-War Illness

    March 18, 2011

    Many questions remain about these chronic multisymptom illnesses

    Using Different Fibromyalgia Criteria Affects Prevalence Estimates

    September 14, 2021

    A recent paper illustrates how using different fibromyalgia criteria affects reports of its prevalence.1 Writing in Arthritis Care & Research, researchers found the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks–American Pain Society Pain Taxonomy (AAPT) criteria caused far more people to be categorized as having fibromyalgia than criteria put forth by…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences